MedTrace Logo

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

NCT00897312 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2016-04-25

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood from patients with cancer, hepatitis C, or Crohn disease in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer and other diseases.

PURPOSE: This laboratory study is looking at the effect of biological therapy on biomarkers in patients with untreated hepatitis C, metastatic melanoma, or Crohn disease.

Conditions

Interventions

BIOLOGICAL

infliximab

BIOLOGICAL

pegylated interferon alfa

BIOLOGICAL

ticilimumab

DRUG

ribavirin

OTHER

high performance liquid chromatography

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Jeffrey A. Sosman, MD · Vanderbilt-Ingram Cancer Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897312 on ClinicalTrials.gov